Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)

Finnish Medicines Agency (Fimea)
Record ID 32018001145
Authors' objectives: This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for BeovuĀ® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and safety of brolucizumab in the target patient population with relevant comparators according to the national requirements of EUnetHTA partners.
Project Status: Completed
URL for project:
Year Published: 2020
URL for published report:
Requestor: HTA agencies
English language abstract: An English language summary is available
Publication Type: Rapid Review
MeSH Terms
  • Antibodies, Monoclonal, Humanized
  • Macular Degeneration
  • Wet Macular Degeneration
  • Adult
  • Angiogenesis Inhibitors
Organisation Name: European Network for Health Technology Assessment
Contact Email:
Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.